Market Currents
Vivus (VVUS -2.5%) slides on concerns that it may be lowering the price of Qsymia just months...
-
Monday, March 4, 10:33 AM ETVivus (VVUS -2.5%) slides on concerns that it may be lowering the price of Qsymia just months after commercial marketing began. Bloomberg's Andrew Berens says the company will start offering 30-days of medium-dose Qsymia for maximum out-of-pocket cost of $75, which is 70% below the current price. The move could pose risks for Arena's (ARNA -4.4%) Belviq, which is a competitor to Qsymia.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 6 comments:
MOUNTAIN VIEW, Calif., March 4, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (VVUS:$10.04,00$-0.30,... today announced that management will present an overview of the company at three investment conferences during the month of March 2013.
The conference presentation schedule is as follows:
Cowen and Company 33rd Annual Health Care Conference
March 5, 2013, 8:00am EST
Boston Marriott Copley Place
Boston, MA
user418 their pills are worth it with the least adverse affect on health and the highest efficacy of weight loss!!
The Save Now! Program is a limited-time-only offer intended for new patients starting Qsymia™ (phentermine and topiramate extended-release) capsules CIV. New patients with a written prescription on or after March 1, 2013 can receive their first 30 days of the recommended dose of Qsymia (7.5 mg/46 mg) for no more than $75, subject to applicable terms and conditions.